OnKure Therapeutics, Inc. (OKUR)Healthcare | Biotechnology | Boulder, United States | NasdaqGM
5.00 USD
+0.33
(7.066%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.90 -0.10 (-0.100%) ⇩ (April 17, 2026, 7:34 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, midnight EDT
Despite massive positive catalysts like a $150M private placement and strong analyst consensus, the negative short-term momentum prediction combined with the company's deep burn rate and lack of dividends suggests a high-risk, high-reward scenario where immediate protection is difficult. Long-term upside remains significant if clinical milestones are hit, but valuations are stretched given the -4.71 EPS and negative cash flow. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.234392 |
| MSTL | 0.242153 |
| AutoETS | 0.243790 |
| AutoTheta | 0.244356 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 4.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.087 |
| Excess Kurtosis | -1.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.977 |
| Market Cap | 68,367,824 |
| Forward P/E | -2.43 |
| Website | https://onkuretherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.83150184 |
| Address1 | 6,707 Winchester Circle |
| Address2 | Suite 400 |
| All Time High | 171.8 |
| All Time Low | 1.7 |
| Ask | 5.07 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 185,000 |
| Average Daily Volume3 Month | 288,675 |
| Average Volume | 288,675 |
| Average Volume10Days | 185,000 |
| Bid | 4.95 |
| Bid Size | 2 |
| Book Value | 4.109 |
| City | Boulder |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.0 |
| Current Ratio | 10.275 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.06 |
| Day Low | 4.67 |
| Debt To Equity | 0.977 |
| Display Name | OnKure Therapeutics |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda | -62,503,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.158 |
| Enterprise Value | 9,866,825 |
| Eps Current Year | -2.655 |
| Eps Forward | -2.05667 |
| Eps Trailing Twelve Months | -4.4 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.5095 |
| Fifty Day Average Change | 1.4905 |
| Fifty Day Average Change Percent | 0.42470437 |
| Fifty Two Week Change Percent | 83.150185 |
| Fifty Two Week High | 5.06 |
| Fifty Two Week High Change | -0.059999943 |
| Fifty Two Week High Change Percent | -0.011857696 |
| Fifty Two Week Low | 1.7 |
| Fifty Two Week Low Change | 3.3 |
| Fifty Two Week Low Change Percent | 1.9411764 |
| Fifty Two Week Range | 1.7 - 5.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,888,600,000 |
| Float Shares | 5,256,802 |
| Forward Eps | -2.05667 |
| Forward P E | -2.4311144 |
| Free Cashflow | -31,100,750 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01705 |
| Held Percent Institutions | 1.46509 |
| Implied Shares Outstanding | 13,673,565 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,728,259,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado. |
| Long Name | OnKure Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 68,367,824 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_142375117 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -59,517,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 71,800,460 |
| Number Of Analyst Opinions | 5 |
| Open | 4.77 |
| Operating Cashflow | -51,828,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 720-307-2892 |
| Post Market Change | -0.099999905 |
| Post Market Change Percent | -1.9999981 |
| Post Market Price | 4.9 |
| Post Market Time | 1,776,468,868 |
| Previous Close | 4.67 |
| Price Eps Current Year | -1.8832392 |
| Price Hint | 4 |
| Price To Book | 1.216841 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.973 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.33 |
| Regular Market Change Percent | 7.06638 |
| Regular Market Day High | 5.06 |
| Regular Market Day Low | 4.67 |
| Regular Market Day Range | 4.67 - 5.06 |
| Regular Market Open | 4.77 |
| Regular Market Previous Close | 4.67 |
| Regular Market Price | 5.0 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 299,095 |
| Return On Assets | -0.4445 |
| Return On Equity | -0.74391 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 13,673,565 |
| Shares Percent Shares Out | 0.012 |
| Shares Short | 163,904 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 53,751 |
| Short Name | OnKure Therapeutics, Inc. |
| Short Percent Of Float | 0.0153 |
| Short Ratio | 0.29 |
| Source Interval | 15 |
| State | CO |
| Symbol | OKUR |
| Target High Price | 30.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 20.2 |
| Target Median Price | 17.0 |
| Total Cash | 59,050,000 |
| Total Cash Per Share | 4.319 |
| Total Debt | 549,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.94605 |
| Two Hundred Day Average Change | 2.05395 |
| Two Hundred Day Average Change Percent | 0.6971878 |
| Type Disp | Equity |
| Volume | 299,095 |
| Website | https://onkuretherapeutics.com |
| Zip | 80,301 |